Trial Outcomes & Findings for SARS-CoV-2/COVID-19 Prevalence Study (NCT NCT04658121)
NCT ID: NCT04658121
Last Updated: 2026-07-16
Results Overview
Prevalence of SARS-CoV-2 antibodies from the enrolled cohorts who provided a blood serum or DBS sample for laboratory analysis.
Recruitment status
COMPLETED
Target enrollment
26211 participants
Primary outcome timeframe
Baseline
Results posted on
2026-07-16
Participant Flow
Participant milestones
| Measure |
Senior Living Facilities
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues Individuals (>2 Months)
Adults and children (\>2 months ) in neighborhoods of selected research sites
|
|---|---|---|---|
|
Overall Study
STARTED
|
806
|
3121
|
22284
|
|
Overall Study
COMPLETED
|
806
|
3121
|
22284
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
SARS-CoV-2/COVID-19 Prevalence Study
Baseline characteristics by cohort
| Measure |
Senior Living Facilities
n=806 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=3111 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues Adults and Children (>2 mo.)
n=22284 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
Total
n=26201 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Customized
<18
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
2113 Participants
n=267 Participants
|
2113 Participants
n=265 Participants
|
|
Age, Customized
18-39
|
12 Participants
n=9 Participants
|
930 Participants
n=27 Participants
|
6813 Participants
n=267 Participants
|
7755 Participants
n=265 Participants
|
|
Age, Customized
40-59
|
62 Participants
n=9 Participants
|
1496 Participants
n=27 Participants
|
7996 Participants
n=267 Participants
|
9554 Participants
n=265 Participants
|
|
Age, Customized
60+
|
732 Participants
n=9 Participants
|
685 Participants
n=27 Participants
|
5347 Participants
n=267 Participants
|
6764 Participants
n=265 Participants
|
|
Age, Customized
missing
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
15 Participants
n=267 Participants
|
15 Participants
n=265 Participants
|
|
Sex/Gender, Customized
Female
|
453 Participants
n=9 Participants
|
1722 Participants
n=27 Participants
|
11122 Participants
n=267 Participants
|
13297 Participants
n=265 Participants
|
|
Sex/Gender, Customized
Male
|
352 Participants
n=9 Participants
|
1389 Participants
n=27 Participants
|
11119 Participants
n=267 Participants
|
12860 Participants
n=265 Participants
|
|
Sex/Gender, Customized
Missing
|
1 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
43 Participants
n=267 Participants
|
44 Participants
n=265 Participants
|
|
Race/Ethnicity, Customized
Race · Black or African American
|
266 Participants
n=9 Participants
|
1604 Participants
n=27 Participants
|
9222 Participants
n=267 Participants
|
11092 Participants
n=265 Participants
|
|
Race/Ethnicity, Customized
Race · White
|
496 Participants
n=9 Participants
|
945 Participants
n=27 Participants
|
8231 Participants
n=267 Participants
|
9672 Participants
n=265 Participants
|
|
Race/Ethnicity, Customized
Race · Other
|
38 Participants
n=9 Participants
|
504 Participants
n=27 Participants
|
4284 Participants
n=267 Participants
|
4826 Participants
n=265 Participants
|
|
Race/Ethnicity, Customized
Race · Prefer not to answer/Don't know
|
4 Participants
n=9 Participants
|
51 Participants
n=27 Participants
|
370 Participants
n=267 Participants
|
425 Participants
n=265 Participants
|
|
Race/Ethnicity, Customized
Race · Missing
|
2 Participants
n=9 Participants
|
7 Participants
n=27 Participants
|
177 Participants
n=267 Participants
|
186 Participants
n=265 Participants
|
|
Race/Ethnicity, Customized
Ethnicity · Hispanic or Latino
|
424 Participants
n=9 Participants
|
1089 Participants
n=27 Participants
|
8775 Participants
n=267 Participants
|
10288 Participants
n=265 Participants
|
|
Race/Ethnicity, Customized
Ethnicity · Not Hispanic or Latino
|
369 Participants
n=9 Participants
|
1976 Participants
n=27 Participants
|
13061 Participants
n=267 Participants
|
15406 Participants
n=265 Participants
|
|
Race/Ethnicity, Customized
Ethnicity · Prefer not to answer/Don't know
|
6 Participants
n=9 Participants
|
23 Participants
n=27 Participants
|
234 Participants
n=267 Participants
|
263 Participants
n=265 Participants
|
|
Race/Ethnicity, Customized
Ethnicity · Missing
|
7 Participants
n=9 Participants
|
23 Participants
n=27 Participants
|
214 Participants
n=267 Participants
|
244 Participants
n=265 Participants
|
|
Region of Enrollment
United States · Atlanta
|
0 Participants
n=9 Participants
|
150 Participants
n=27 Participants
|
1489 Participants
n=267 Participants
|
1639 Participants
n=265 Participants
|
|
Region of Enrollment
United States · Aurora, CO
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
839 Participants
n=267 Participants
|
839 Participants
n=265 Participants
|
|
Region of Enrollment
United States · Baltimore
|
0 Participants
n=9 Participants
|
145 Participants
n=27 Participants
|
877 Participants
n=267 Participants
|
1022 Participants
n=265 Participants
|
|
Region of Enrollment
United States · Bronx
|
0 Participants
n=9 Participants
|
14 Participants
n=27 Participants
|
2546 Participants
n=267 Participants
|
2560 Participants
n=265 Participants
|
|
Region of Enrollment
United States · Chicago
|
111 Participants
n=9 Participants
|
335 Participants
n=27 Participants
|
1246 Participants
n=267 Participants
|
1692 Participants
n=265 Participants
|
|
Region of Enrollment
United States · Cincinnati
|
12 Participants
n=9 Participants
|
35 Participants
n=27 Participants
|
1188 Participants
n=267 Participants
|
1235 Participants
n=265 Participants
|
|
Region of Enrollment
United States · Harlem
|
0 Participants
n=9 Participants
|
503 Participants
n=27 Participants
|
2672 Participants
n=267 Participants
|
3175 Participants
n=265 Participants
|
|
Region of Enrollment
United States · Houston
|
32 Participants
n=9 Participants
|
151 Participants
n=27 Participants
|
1174 Participants
n=267 Participants
|
1357 Participants
n=265 Participants
|
|
Region of Enrollment
United States · Miami
|
0 Participants
n=9 Participants
|
0 Participants
n=27 Participants
|
1480 Participants
n=267 Participants
|
1480 Participants
n=265 Participants
|
|
Region of Enrollment
United States · New Orleans
|
201 Participants
n=9 Participants
|
73 Participants
n=27 Participants
|
1799 Participants
n=267 Participants
|
2073 Participants
n=265 Participants
|
|
Region of Enrollment
United States · New York - Columbia
|
0 Participants
n=9 Participants
|
265 Participants
n=27 Participants
|
508 Participants
n=267 Participants
|
773 Participants
n=265 Participants
|
|
Region of Enrollment
United States · Newark
|
0 Participants
n=9 Participants
|
262 Participants
n=27 Participants
|
861 Participants
n=267 Participants
|
1123 Participants
n=265 Participants
|
|
Region of Enrollment
United States · Philadelphia
|
0 Participants
n=9 Participants
|
539 Participants
n=27 Participants
|
1564 Participants
n=267 Participants
|
2103 Participants
n=265 Participants
|
|
Region of Enrollment
United States · Pittsburgh
|
47 Participants
n=9 Participants
|
139 Participants
n=27 Participants
|
1117 Participants
n=267 Participants
|
1303 Participants
n=265 Participants
|
|
Region of Enrollment
United States · Ponce, Puerto Rico
|
403 Participants
n=9 Participants
|
500 Participants
n=27 Participants
|
2924 Participants
n=267 Participants
|
3827 Participants
n=265 Participants
|
PRIMARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who provided a blood serum or DBS sample and had a result from laboratory analysis. Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older.
Prevalence of SARS-CoV-2 antibodies from the enrolled cohorts who provided a blood serum or DBS sample for laboratory analysis.
Outcome measures
| Measure |
Senior Living Facilities
n=780 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=2943 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=21009 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Estimate the Prevalence of SARS-CoV-2 IgG Seropositivity Among Individuals in Communities Surrounding Selected NIAID Clinical Research Sites
Baltimore
|
0 Participants
|
24 Participants
|
102 Participants
|
|
To Estimate the Prevalence of SARS-CoV-2 IgG Seropositivity Among Individuals in Communities Surrounding Selected NIAID Clinical Research Sites
Bronx
|
0 Participants
|
3 Participants
|
420 Participants
|
|
To Estimate the Prevalence of SARS-CoV-2 IgG Seropositivity Among Individuals in Communities Surrounding Selected NIAID Clinical Research Sites
Chicago
|
21 Participants
|
50 Participants
|
129 Participants
|
|
To Estimate the Prevalence of SARS-CoV-2 IgG Seropositivity Among Individuals in Communities Surrounding Selected NIAID Clinical Research Sites
Cincinnati
|
4 Participants
|
5 Participants
|
94 Participants
|
|
To Estimate the Prevalence of SARS-CoV-2 IgG Seropositivity Among Individuals in Communities Surrounding Selected NIAID Clinical Research Sites
Harlem
|
0 Participants
|
71 Participants
|
330 Participants
|
|
To Estimate the Prevalence of SARS-CoV-2 IgG Seropositivity Among Individuals in Communities Surrounding Selected NIAID Clinical Research Sites
Houston
|
1 Participants
|
11 Participants
|
136 Participants
|
|
To Estimate the Prevalence of SARS-CoV-2 IgG Seropositivity Among Individuals in Communities Surrounding Selected NIAID Clinical Research Sites
Miami
|
0 Participants
|
0 Participants
|
205 Participants
|
|
To Estimate the Prevalence of SARS-CoV-2 IgG Seropositivity Among Individuals in Communities Surrounding Selected NIAID Clinical Research Sites
New Orleans
|
15 Participants
|
8 Participants
|
145 Participants
|
|
To Estimate the Prevalence of SARS-CoV-2 IgG Seropositivity Among Individuals in Communities Surrounding Selected NIAID Clinical Research Sites
New York - Columbia
|
0 Participants
|
41 Participants
|
80 Participants
|
|
To Estimate the Prevalence of SARS-CoV-2 IgG Seropositivity Among Individuals in Communities Surrounding Selected NIAID Clinical Research Sites
Newark
|
0 Participants
|
47 Participants
|
128 Participants
|
|
To Estimate the Prevalence of SARS-CoV-2 IgG Seropositivity Among Individuals in Communities Surrounding Selected NIAID Clinical Research Sites
Philadelphia
|
0 Participants
|
53 Participants
|
189 Participants
|
|
To Estimate the Prevalence of SARS-CoV-2 IgG Seropositivity Among Individuals in Communities Surrounding Selected NIAID Clinical Research Sites
Pittsburg
|
1 Participants
|
19 Participants
|
84 Participants
|
|
To Estimate the Prevalence of SARS-CoV-2 IgG Seropositivity Among Individuals in Communities Surrounding Selected NIAID Clinical Research Sites
Ponce. Puerto Rico
|
6 Participants
|
19 Participants
|
111 Participants
|
|
To Estimate the Prevalence of SARS-CoV-2 IgG Seropositivity Among Individuals in Communities Surrounding Selected NIAID Clinical Research Sites
Atlanta
|
0 Participants
|
13 Participants
|
142 Participants
|
|
To Estimate the Prevalence of SARS-CoV-2 IgG Seropositivity Among Individuals in Communities Surrounding Selected NIAID Clinical Research Sites
Aurora, CO
|
0 Participants
|
0 Participants
|
85 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who provided a nasal swab and had a result from laboratory analysis. Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older.
Prevalence of active SARS-CoV-2 infection from the enrolled cohorts who provided a nasal swab sample for PCR laboratory analysis.
Outcome measures
| Measure |
Senior Living Facilities
n=784 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=3086 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=21985 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Estimate Prevalence of SARS-CoV-2 Infection Based on Results of SARS-CoV-2 RNA Testing
Atlanta
|
0 Participants
|
0 Participants
|
4 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Based on Results of SARS-CoV-2 RNA Testing
Aurora, CO
|
0 Participants
|
0 Participants
|
3 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Based on Results of SARS-CoV-2 RNA Testing
Baltimore
|
0 Participants
|
4 Participants
|
12 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Based on Results of SARS-CoV-2 RNA Testing
Bronx
|
0 Participants
|
0 Participants
|
35 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Based on Results of SARS-CoV-2 RNA Testing
Chicago
|
0 Participants
|
2 Participants
|
12 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Based on Results of SARS-CoV-2 RNA Testing
Cincinnati
|
0 Participants
|
0 Participants
|
13 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Based on Results of SARS-CoV-2 RNA Testing
Harlem
|
0 Participants
|
0 Participants
|
22 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Based on Results of SARS-CoV-2 RNA Testing
Houston
|
0 Participants
|
1 Participants
|
16 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Based on Results of SARS-CoV-2 RNA Testing
Miami
|
0 Participants
|
0 Participants
|
9 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Based on Results of SARS-CoV-2 RNA Testing
New Orleans
|
0 Participants
|
0 Participants
|
11 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Based on Results of SARS-CoV-2 RNA Testing
New York - Columbia
|
0 Participants
|
1 Participants
|
0 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Based on Results of SARS-CoV-2 RNA Testing
Newark
|
0 Participants
|
2 Participants
|
1 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Based on Results of SARS-CoV-2 RNA Testing
Philadelphia
|
0 Participants
|
6 Participants
|
26 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Based on Results of SARS-CoV-2 RNA Testing
Pittsburg
|
0 Participants
|
0 Participants
|
4 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Based on Results of SARS-CoV-2 RNA Testing
Ponce, Puerto Rico
|
0 Participants
|
6 Participants
|
28 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who provided a nasal swab, had a result from laboratory analysis, and reported presense of any symptom consistent with COVID-19. Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older.
Prevalence of active SARS-CoV-2 infection from the enrolled cohorts who provided a nasal swab sample, had a result from PCR laboratory analysis, and reported any symptom consistent with COVID-19 (symptoms include fever, headache, cough, congestion, etc...).
Outcome measures
| Measure |
Senior Living Facilities
n=81 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=445 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=3679 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Presence of Symptoms Consistent With COVID-19
Atlanta
|
0 Participants
|
0 Participants
|
2 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Presence of Symptoms Consistent With COVID-19
Aurora, CO
|
0 Participants
|
0 Participants
|
1 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Presence of Symptoms Consistent With COVID-19
Baltimore
|
0 Participants
|
3 Participants
|
5 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Presence of Symptoms Consistent With COVID-19
Bronx
|
0 Participants
|
0 Participants
|
16 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Presence of Symptoms Consistent With COVID-19
Chicago
|
0 Participants
|
0 Participants
|
5 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Presence of Symptoms Consistent With COVID-19
Cincinnati
|
0 Participants
|
0 Participants
|
8 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Presence of Symptoms Consistent With COVID-19
Harlem
|
0 Participants
|
0 Participants
|
8 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Presence of Symptoms Consistent With COVID-19
Houston
|
0 Participants
|
0 Participants
|
7 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Presence of Symptoms Consistent With COVID-19
Miami
|
0 Participants
|
0 Participants
|
4 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Presence of Symptoms Consistent With COVID-19
New Orleans
|
0 Participants
|
0 Participants
|
7 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Presence of Symptoms Consistent With COVID-19
New York - Columbia
|
0 Participants
|
0 Participants
|
0 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Presence of Symptoms Consistent With COVID-19
Newark
|
0 Participants
|
1 Participants
|
0 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Presence of Symptoms Consistent With COVID-19
Philadelphia
|
0 Participants
|
5 Participants
|
13 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Presence of Symptoms Consistent With COVID-19
Pittsburgh
|
0 Participants
|
0 Participants
|
2 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Presence of Symptoms Consistent With COVID-19
Ponce, Puerto Rico
|
0 Participants
|
2 Participants
|
13 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who provided a nasal swab, had a result from laboratory analysis, and reported no symptoms consistent with COVID-19. Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older.
Prevalence of active SARS-CoV-2 infection from the enrolled cohorts who provided a nasal swab sample, had a result from PCR laboratory analysis, and reported no symptoms consistent with COVID-19 (symptoms include fever, headache, cough, congestion, etc...).
Outcome measures
| Measure |
Senior Living Facilities
n=638 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=2483 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=16839 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Absence of Symptoms Consistent With COVID-19
Atlanta
|
0 Participants
|
0 Participants
|
0 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Absence of Symptoms Consistent With COVID-19
Aurora, CO
|
0 Participants
|
0 Participants
|
0 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Absence of Symptoms Consistent With COVID-19
Baltimore
|
0 Participants
|
1 Participants
|
7 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Absence of Symptoms Consistent With COVID-19
Bronx
|
0 Participants
|
0 Participants
|
17 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Absence of Symptoms Consistent With COVID-19
Chicago
|
0 Participants
|
2 Participants
|
7 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Absence of Symptoms Consistent With COVID-19
Cincinnati
|
0 Participants
|
0 Participants
|
5 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Absence of Symptoms Consistent With COVID-19
Harlem
|
0 Participants
|
0 Participants
|
12 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Absence of Symptoms Consistent With COVID-19
Houston
|
0 Participants
|
0 Participants
|
7 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Absence of Symptoms Consistent With COVID-19
Miami
|
0 Participants
|
0 Participants
|
5 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Absence of Symptoms Consistent With COVID-19
New Orleans
|
0 Participants
|
0 Participants
|
4 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Absence of Symptoms Consistent With COVID-19
New York - Columbia
|
0 Participants
|
1 Participants
|
0 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Absence of Symptoms Consistent With COVID-19
Newark
|
0 Participants
|
1 Participants
|
1 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Absence of Symptoms Consistent With COVID-19
Philadelphia
|
0 Participants
|
1 Participants
|
13 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Absence of Symptoms Consistent With COVID-19
Pittsburgh
|
0 Participants
|
0 Participants
|
2 Participants
|
|
To Estimate Prevalence of SARS-CoV-2 Infection Among Those Reporting Absence of Symptoms Consistent With COVID-19
Ponce, Puerto Rico
|
0 Participants
|
4 Participants
|
14 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who provided a blood serum or DBS sample, had a result from laboratory analysis, and reported no past or current symptoms consistent with COVID-19. Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older.
Prevalence of SARS-CoV-2 antibodies from the enrolled cohorts who provided a blood serum or DBS sample, had a result from laboratory analysis, and reported no past or current symptoms consistent with COVID-19 (symptoms include fever, headache, cough, congestion, etc...).
Outcome measures
| Measure |
Senior Living Facilities
n=603 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=1900 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=12914 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those Without Past or Current Symptoms Consistent With COVID-19
Atlanta
|
0 Participants
|
2 Participants
|
28 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those Without Past or Current Symptoms Consistent With COVID-19
Aurora, CO
|
0 Participants
|
0 Participants
|
27 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those Without Past or Current Symptoms Consistent With COVID-19
Baltimore
|
0 Participants
|
8 Participants
|
56 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those Without Past or Current Symptoms Consistent With COVID-19
Bronx
|
0 Participants
|
0 Participants
|
186 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those Without Past or Current Symptoms Consistent With COVID-19
Chicago
|
13 Participants
|
17 Participants
|
63 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those Without Past or Current Symptoms Consistent With COVID-19
Cincinnati
|
0 Participants
|
1 Participants
|
37 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those Without Past or Current Symptoms Consistent With COVID-19
Harlem
|
0 Participants
|
34 Participants
|
178 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those Without Past or Current Symptoms Consistent With COVID-19
Houston
|
1 Participants
|
7 Participants
|
56 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those Without Past or Current Symptoms Consistent With COVID-19
Miami
|
0 Participants
|
0 Participants
|
86 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those Without Past or Current Symptoms Consistent With COVID-19
New Orleans
|
6 Participants
|
4 Participants
|
51 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those Without Past or Current Symptoms Consistent With COVID-19
New York - Columbia
|
0 Participants
|
11 Participants
|
15 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those Without Past or Current Symptoms Consistent With COVID-19
Newark
|
0 Participants
|
11 Participants
|
58 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those Without Past or Current Symptoms Consistent With COVID-19
Philadelphia
|
0 Participants
|
29 Participants
|
128 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those Without Past or Current Symptoms Consistent With COVID-19
Pittsburgh
|
0 Participants
|
2 Participants
|
34 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those Without Past or Current Symptoms Consistent With COVID-19
Ponce, Puerto Rico
|
5 Participants
|
12 Participants
|
61 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who provided a blood serum or DBS sample, had a result from laboratory analysis, report no prior positive SARS-CoV-2 testing but did report close contact with confirmed or presumed case. Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older.
Prevalence of SARS-CoV-2 antibodies from the enrolled cohorts who provided a blood serum or DBS sample, had a result from laboratory analysis, and reported no prior positive SARS-CoV-2 testing but did report close contact with confirmed or presumed cases.
Outcome measures
| Measure |
Senior Living Facilities
n=7 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=164 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=1121 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With no Prior Positive SARS-CoV-2 Testing, But Who Report Close Contact With Confirmed or Presumed Cases
Atlanta
|
0 Participants
|
0 Participants
|
2 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With no Prior Positive SARS-CoV-2 Testing, But Who Report Close Contact With Confirmed or Presumed Cases
Aurora, CO
|
0 Participants
|
0 Participants
|
3 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With no Prior Positive SARS-CoV-2 Testing, But Who Report Close Contact With Confirmed or Presumed Cases
Baltimore
|
0 Participants
|
2 Participants
|
3 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With no Prior Positive SARS-CoV-2 Testing, But Who Report Close Contact With Confirmed or Presumed Cases
Bronx
|
0 Participants
|
0 Participants
|
26 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With no Prior Positive SARS-CoV-2 Testing, But Who Report Close Contact With Confirmed or Presumed Cases
Chicago
|
1 Participants
|
3 Participants
|
9 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With no Prior Positive SARS-CoV-2 Testing, But Who Report Close Contact With Confirmed or Presumed Cases
Cincinnati
|
0 Participants
|
1 Participants
|
1 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With no Prior Positive SARS-CoV-2 Testing, But Who Report Close Contact With Confirmed or Presumed Cases
Harlem
|
0 Participants
|
1 Participants
|
11 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With no Prior Positive SARS-CoV-2 Testing, But Who Report Close Contact With Confirmed or Presumed Cases
Houston
|
0 Participants
|
1 Participants
|
1 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With no Prior Positive SARS-CoV-2 Testing, But Who Report Close Contact With Confirmed or Presumed Cases
Miami
|
0 Participants
|
0 Participants
|
4 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With no Prior Positive SARS-CoV-2 Testing, But Who Report Close Contact With Confirmed or Presumed Cases
New Orleans
|
0 Participants
|
0 Participants
|
6 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With no Prior Positive SARS-CoV-2 Testing, But Who Report Close Contact With Confirmed or Presumed Cases
New York - Columbia
|
0 Participants
|
0 Participants
|
2 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With no Prior Positive SARS-CoV-2 Testing, But Who Report Close Contact With Confirmed or Presumed Cases
Newark
|
0 Participants
|
3 Participants
|
4 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With no Prior Positive SARS-CoV-2 Testing, But Who Report Close Contact With Confirmed or Presumed Cases
Philadelphia
|
0 Participants
|
4 Participants
|
12 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With no Prior Positive SARS-CoV-2 Testing, But Who Report Close Contact With Confirmed or Presumed Cases
Pittsburgh
|
0 Participants
|
0 Participants
|
5 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With no Prior Positive SARS-CoV-2 Testing, But Who Report Close Contact With Confirmed or Presumed Cases
Ponce, Puerto Rico
|
0 Participants
|
1 Participants
|
15 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who provided a blood serum or DBS sample, had a result from laboratory analysis, and reported any co-morbid medical condition (which includes asthma, hypertension, diabetes, etc...). Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older.
Prevalence of SARS-CoV-2 antibodies from the enrolled cohorts who provided a blood serum or DBS sample, had a result from laboratory analysis, and reported any co-morbid medical condition (which includes asthma, hypertension, diabetes, etc...)
Outcome measures
| Measure |
Senior Living Facilities
n=649 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=2040 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=12075 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With History of Co-morbid Medical Conditions
Chicago
|
19 Participants
|
41 Participants
|
79 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With History of Co-morbid Medical Conditions
Cincinnati
|
2 Participants
|
3 Participants
|
43 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With History of Co-morbid Medical Conditions
Harlem
|
0 Participants
|
48 Participants
|
184 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With History of Co-morbid Medical Conditions
Houston
|
1 Participants
|
8 Participants
|
84 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With History of Co-morbid Medical Conditions
Miami
|
0 Participants
|
0 Participants
|
105 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With History of Co-morbid Medical Conditions
New Orleans
|
14 Participants
|
8 Participants
|
104 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With History of Co-morbid Medical Conditions
New York - Columbia
|
0 Participants
|
30 Participants
|
60 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With History of Co-morbid Medical Conditions
Newark
|
0 Participants
|
31 Participants
|
107 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With History of Co-morbid Medical Conditions
Philadelphia
|
0 Participants
|
36 Participants
|
136 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With History of Co-morbid Medical Conditions
Bronx
|
0 Participants
|
3 Participants
|
239 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With History of Co-morbid Medical Conditions
Atlanta
|
0 Participants
|
3 Participants
|
49 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With History of Co-morbid Medical Conditions
Aurora, CO
|
0 Participants
|
0 Participants
|
49 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With History of Co-morbid Medical Conditions
Baltimore
|
0 Participants
|
21 Participants
|
76 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With History of Co-morbid Medical Conditions
Pittsburgh
|
1 Participants
|
17 Participants
|
56 Participants
|
|
To Estimate Seroprevalence of SARS-CoV-2 Among Those With History of Co-morbid Medical Conditions
Ponce, Puerto Rico
|
4 Participants
|
7 Participants
|
58 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who provided a blood serum, DBS, or nasal swab sample, had a result from laboratory analysis, and had a non-missing age response. Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older.
Prevalence of SARS-CoV-2 infection and/or antibodies from the enrolled cohorts who provided a blood serum, DBS, or nasal swab sample and had a result from laboratory analysis. Results are reported by site and by age group (0-17, 18-39, 40-59, 60+).
Outcome measures
| Measure |
Senior Living Facilities
n=805 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=3107 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=22181 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Atlanta : 0-17 years old
|
0 Participants
|
0 Participants
|
3 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Atlanta : 18-39 years old
|
0 Participants
|
5 Participants
|
61 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Atlanta : 40-59 years old
|
0 Participants
|
6 Participants
|
51 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Atlanta : 60+ years old
|
0 Participants
|
2 Participants
|
31 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Aurora, CO : 0-17 years old
|
0 Participants
|
0 Participants
|
9 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Aurora, CO : 18-39 years old
|
0 Participants
|
0 Participants
|
23 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Aurora, CO : 40-59 years old
|
0 Participants
|
0 Participants
|
39 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Aurora, CO : 60+ years old
|
0 Participants
|
0 Participants
|
16 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Baltimore : 0-17 years old
|
0 Participants
|
0 Participants
|
6 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Baltimore : 18-39 years old
|
0 Participants
|
11 Participants
|
21 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Baltimore : 40-59 years old
|
0 Participants
|
11 Participants
|
59 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Baltimore : 60+ years old
|
0 Participants
|
5 Participants
|
25 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Bronx : 0-17 years old
|
0 Participants
|
0 Participants
|
82 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Bronx : 18-39 years old
|
0 Participants
|
0 Participants
|
112 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Bronx : 40-59 years old
|
0 Participants
|
2 Participants
|
138 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Bronx : 60+ years old
|
0 Participants
|
1 Participants
|
113 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Chicago : 0-17 years old
|
0 Participants
|
0 Participants
|
2 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Chicago : 18-39 years old
|
1 Participants
|
15 Participants
|
35 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Chicago : 40-59 years old
|
7 Participants
|
19 Participants
|
68 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Chicago : 60+ years old
|
13 Participants
|
18 Participants
|
33 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Cincinnati : 0-17 years old
|
0 Participants
|
0 Participants
|
3 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Cincinnati : 18-39 years old
|
1 Participants
|
1 Participants
|
42 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Cincinnati : 40-59 years old
|
0 Participants
|
2 Participants
|
37 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Cincinnati : 60+ years old
|
3 Participants
|
2 Participants
|
22 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Harlem : 0-17 years old
|
0 Participants
|
0 Participants
|
38 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Harlem : 18-39 years old
|
0 Participants
|
10 Participants
|
89 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Harlem : 40-59 years old
|
0 Participants
|
42 Participants
|
106 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Harlem : 60+ years old
|
0 Participants
|
19 Participants
|
116 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Houston : 0-17 years old
|
0 Participants
|
0 Participants
|
10 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Houston : 18-39 years old
|
0 Participants
|
2 Participants
|
40 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Houston : 40-59 years old
|
0 Participants
|
9 Participants
|
66 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Houston : 60+ years old
|
1 Participants
|
0 Participants
|
30 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Miami : 0-17 years old
|
0 Participants
|
0 Participants
|
10 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Miami : 18-39 years old
|
0 Participants
|
0 Participants
|
65 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Miami : 40-59 years old
|
0 Participants
|
0 Participants
|
82 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Miami : 60+ years old
|
0 Participants
|
0 Participants
|
57 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
New Orleans : 0-17 years old
|
0 Participants
|
0 Participants
|
14 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
New Orleans : 18-39 years old
|
0 Participants
|
0 Participants
|
34 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
New Orleans : 40-59 years old
|
0 Participants
|
6 Participants
|
59 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
New Orleans : 60+ years old
|
15 Participants
|
2 Participants
|
47 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
New York - Columbia : 0-17 years old
|
0 Participants
|
0 Participants
|
0 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
New York - Columbia : 18-39 years old
|
0 Participants
|
7 Participants
|
19 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
New York - Columbia : 40-59 years old
|
0 Participants
|
20 Participants
|
29 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
New York - Columbia : 60+ years old
|
0 Participants
|
14 Participants
|
32 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Newark : 0-17 years old
|
0 Participants
|
0 Participants
|
2 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Newark : 18-39 years old
|
0 Participants
|
17 Participants
|
22 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Newark : 40-59 years old
|
0 Participants
|
21 Participants
|
67 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Newark : 60+ years old
|
0 Participants
|
9 Participants
|
38 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Philadelphia : 0-17 years old
|
0 Participants
|
0 Participants
|
5 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Philadelphia : 18-39 years old
|
0 Participants
|
10 Participants
|
56 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Philadelphia : 40-59 years old
|
0 Participants
|
31 Participants
|
94 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Philadelphia : 60+ years old
|
0 Participants
|
16 Participants
|
50 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Pittsburgh : 0-17 years old
|
0 Participants
|
0 Participants
|
0 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Pittsburgh : 18-39 years old
|
0 Participants
|
5 Participants
|
32 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Pittsburgh : 40-59 years old
|
0 Participants
|
10 Participants
|
32 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Pittsburgh : 60+ years old
|
1 Participants
|
4 Participants
|
23 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Ponce, Puerto Rico : 0-17 years old
|
0 Participants
|
0 Participants
|
32 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Ponce, Puerto Rico : 18-39 years old
|
0 Participants
|
11 Participants
|
37 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Ponce, Puerto Rico : 40-59 years old
|
0 Participants
|
7 Participants
|
35 Participants
|
|
To Assess Association Between Age and SARS-CoV-2 Infection and/or Seroprevalence
Ponce, Puerto Rico : 60+ years old
|
6 Participants
|
2 Participants
|
24 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who provided a blood serum, DBS, or nasal swab sample, had a result from laboratory analysis, and had a non-missing sex response. Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older.
Prevalence of SARS-CoV-2 infection and/or antibodies from the enrolled cohorts who provided a blood serum, DBS, or nasal swab sample and had a result from laboratory analysis. Results are reported by site and by sex.
Outcome measures
| Measure |
Senior Living Facilities
n=804 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=3107 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=22153 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Baltimore: Males
|
0 Participants
|
15 Participants
|
57 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Bronx: Females
|
0 Participants
|
2 Participants
|
236 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Bronx: Males
|
0 Participants
|
1 Participants
|
209 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Chicago: Females
|
6 Participants
|
32 Participants
|
54 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Chicago: Males
|
15 Participants
|
20 Participants
|
84 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Cincinnati: Females
|
2 Participants
|
3 Participants
|
48 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Cincinnati: Males
|
2 Participants
|
2 Participants
|
56 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Harlem: Females
|
0 Participants
|
48 Participants
|
181 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Harlem: Males
|
0 Participants
|
23 Participants
|
168 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Houston: Females
|
1 Participants
|
6 Participants
|
104 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Houston: Males
|
0 Participants
|
5 Participants
|
42 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Miami: Females
|
0 Participants
|
0 Participants
|
99 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Miami: Males
|
0 Participants
|
0 Participants
|
115 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
New Orleans: Females
|
8 Participants
|
1 Participants
|
76 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
New Orleans: Males
|
7 Participants
|
7 Participants
|
78 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
New York - Columbia: Females
|
0 Participants
|
24 Participants
|
43 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Atlanta: Females
|
0 Participants
|
11 Participants
|
46 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Atlanta: Males
|
0 Participants
|
2 Participants
|
98 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Aurora, CO: Females
|
0 Participants
|
0 Participants
|
48 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Aurora, CO: Males
|
0 Participants
|
0 Participants
|
39 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Baltimore: Females
|
0 Participants
|
12 Participants
|
54 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
New York - Columbia: Males
|
0 Participants
|
17 Participants
|
37 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Newark: Females
|
0 Participants
|
38 Participants
|
71 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Newark: Males
|
0 Participants
|
9 Participants
|
58 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Philadelphia: Females
|
0 Participants
|
20 Participants
|
77 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Philadelphia: Males
|
0 Participants
|
37 Participants
|
128 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Pittsburgh: Females
|
0 Participants
|
10 Participants
|
45 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Pittsburgh: Males
|
1 Participants
|
9 Participants
|
42 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Ponce, Puerto Rico: Females
|
5 Participants
|
11 Participants
|
65 Participants
|
|
To Assess Association Between Sex and SARS-CoV-2 Infection and/or Seroprevalence
Ponce, Puerto Rico: Males
|
1 Participants
|
9 Participants
|
62 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who provided a blood serum, DBS, or nasal swab sample, had a result from laboratory analysis, and had a non-missing race response. Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older.
Prevalence of SARS-CoV-2 infection and/or antibodies from the enrolled cohorts who provided a blood serum, DBS, or nasal swab sample and had a result from laboratory analysis. Results are reported by site and by racial category. The racial group "Other" includes responses of Other, Multiple Races, Asian, Native Hawaiian or other Pacific Islander, American Indian or Alaskan Native, as well as don't know/not sure or prefer not to answer.
Outcome measures
| Measure |
Senior Living Facilities
n=799 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=3048 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=21651 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Bronx : Other
|
0 Participants
|
3 Participants
|
203 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Chicago : Black
|
13 Participants
|
30 Participants
|
65 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Chicago : White
|
6 Participants
|
12 Participants
|
17 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Atlanta : Black
|
0 Participants
|
10 Participants
|
78 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Atlanta : White
|
0 Participants
|
3 Participants
|
40 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Atlanta : Other
|
0 Participants
|
0 Participants
|
22 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Chicago : Other
|
2 Participants
|
10 Participants
|
52 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Aurora, CO : Black
|
0 Participants
|
0 Participants
|
25 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Aurora, CO : White
|
0 Participants
|
0 Participants
|
28 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Aurora, CO : Other
|
0 Participants
|
0 Participants
|
32 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Baltimore : Black
|
0 Participants
|
23 Participants
|
106 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Baltimore : White
|
0 Participants
|
3 Participants
|
2 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Baltimore : Other
|
0 Participants
|
0 Participants
|
3 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Bronx : Black
|
0 Participants
|
0 Participants
|
162 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
New Orleans : Black
|
14 Participants
|
8 Participants
|
114 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
New Orleans : White
|
1 Participants
|
0 Participants
|
32 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Cincinnati : Black
|
0 Participants
|
4 Participants
|
35 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Cincinnati : White
|
4 Participants
|
1 Participants
|
57 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
New Orleans : Other
|
0 Participants
|
0 Participants
|
6 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
New York - Columbia : Black
|
0 Participants
|
10 Participants
|
20 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
New York - Columbia : White
|
0 Participants
|
2 Participants
|
14 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
New York - Columbia : Other
|
0 Participants
|
27 Participants
|
40 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Newark : Black
|
0 Participants
|
25 Participants
|
104 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Newark : White
|
0 Participants
|
12 Participants
|
7 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Newark : Other
|
0 Participants
|
10 Participants
|
17 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Philadelphia : Black
|
0 Participants
|
45 Participants
|
137 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Philadelphia : White
|
0 Participants
|
10 Participants
|
48 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Philadelphia : Other
|
0 Participants
|
2 Participants
|
20 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Pittsburgh : Black
|
0 Participants
|
9 Participants
|
25 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Pittsburgh : White
|
1 Participants
|
5 Participants
|
46 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Pittsburgh : Other
|
0 Participants
|
5 Participants
|
14 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Ponce, Puerto Rico : Black
|
1 Participants
|
6 Participants
|
10 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Ponce, Puerto Rico : White
|
5 Participants
|
13 Participants
|
109 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Ponce, Puerto Rico : Other
|
0 Participants
|
1 Participants
|
9 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Bronx : White
|
0 Participants
|
0 Participants
|
50 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Cincinnati : Other
|
0 Participants
|
0 Participants
|
12 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Harlem : Black
|
0 Participants
|
53 Participants
|
207 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Harlem : White
|
0 Participants
|
2 Participants
|
17 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Harlem : Other
|
0 Participants
|
16 Participants
|
117 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Houston : Black
|
0 Participants
|
8 Participants
|
38 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Houston : White
|
1 Participants
|
3 Participants
|
98 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Houston : Other
|
0 Participants
|
0 Participants
|
10 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Miami : Black
|
0 Participants
|
0 Participants
|
53 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Miami : White
|
0 Participants
|
0 Participants
|
140 Participants
|
|
To Assess Association Between Race and SARS-CoV-2 Infection and/or Seroprevalence
Miami : Other
|
0 Participants
|
0 Participants
|
17 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who provided a blood serum, DBS, or nasal swab sample, had a result from laboratory analysis, and had a non-missing ethnicity response. Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older.
Prevalence of SARS-CoV-2 infection and/or antibodies from the enrolled cohorts who provided a blood serum, DBS, or nasal swab sample, had a result from laboratory analysis, and had a non-missing ethnicity response. Results are reported by site and by ethnicity.
Outcome measures
| Measure |
Senior Living Facilities
n=792 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=3061 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=21752 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Aurora, CO : Hispanic
|
0 Participants
|
0 Participants
|
45 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Atlanta : Hispanic
|
0 Participants
|
3 Participants
|
23 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Atlanta : Non-Hispanic
|
0 Participants
|
10 Participants
|
111 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Aurora, CO : Non-Hispanic
|
0 Participants
|
0 Participants
|
42 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Baltimore : Hispanic
|
0 Participants
|
0 Participants
|
1 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Baltimore : Non-Hispanic
|
0 Participants
|
25 Participants
|
107 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Bronx : Hispanic
|
0 Participants
|
2 Participants
|
308 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Bronx : Non-Hispanic
|
0 Participants
|
0 Participants
|
133 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Chicago : Hispanic
|
2 Participants
|
16 Participants
|
63 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Chicago : Non-Hispanic
|
19 Participants
|
36 Participants
|
74 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Cincinnati : Hispanic
|
0 Participants
|
0 Participants
|
2 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Cincinnati : Non-Hispanic
|
4 Participants
|
5 Participants
|
100 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Harlem : Hispanic
|
0 Participants
|
20 Participants
|
121 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Harlem : Non-Hispanic
|
0 Participants
|
50 Participants
|
224 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Houston : Hispanic
|
0 Participants
|
2 Participants
|
83 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Houston : Non-Hispanic
|
1 Participants
|
9 Participants
|
63 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Miami : Hispanic
|
0 Participants
|
0 Participants
|
158 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Miami : Non-Hispanic
|
0 Participants
|
0 Participants
|
52 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
New Orleans : Hispanic
|
0 Participants
|
0 Participants
|
13 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
New Orleans : Non-Hispanic
|
14 Participants
|
8 Participants
|
141 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
New York - Columbia : Hispanic
|
0 Participants
|
30 Participants
|
54 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
New York - Columbia : Non-Hispanic
|
0 Participants
|
11 Participants
|
25 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Newark : Hispanic
|
0 Participants
|
14 Participants
|
17 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Newark : Non-Hispanic
|
0 Participants
|
33 Participants
|
109 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Philadelphia : Hispanic
|
0 Participants
|
1 Participants
|
19 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Philadelphia : Non-Hispanic
|
0 Participants
|
56 Participants
|
183 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Pittsburgh : Hispanic
|
0 Participants
|
2 Participants
|
16 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Pittsburgh : Non-Hispanic
|
1 Participants
|
17 Participants
|
65 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Ponce, Puerto Rico : Hispanic
|
6 Participants
|
20 Participants
|
124 Participants
|
|
To Assess Association Between Ethnicity and SARS-CoV-2 Infection and/or Seroprevalence
Ponce, Puerto Rico : Non-Hispanic
|
0 Participants
|
0 Participants
|
1 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who provided a blood serum, DBS, or nasal swab sample, had a result from laboratory analysis, and had a non-missing education response. Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older.
Prevalence of SARS-CoV-2 infection and/or antibodies from the enrolled cohorts who provided a blood serum, DBS, or nasal swab sample and had a result from laboratory analysis. Results are reported by site and by education level. The category of "College Degree" includes college, univesity or post-graduate degree. The category of "Middle School or Under" includes middle School (6th-8th grade), elementary school (1st-5th grade), kindergarten, pre-kindergarten, or no formal education.
Outcome measures
| Measure |
Senior Living Facilities
n=800 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=3107 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=22129 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Atlanta : College Degree
|
0 Participants
|
8 Participants
|
64 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Atlanta : High School/Some College
|
0 Participants
|
5 Participants
|
70 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Atlanta : Middle School or Under
|
0 Participants
|
0 Participants
|
10 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Aurora, CO : College Degree
|
0 Participants
|
0 Participants
|
15 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Aurora, CO : High School/Some College
|
0 Participants
|
0 Participants
|
45 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Aurora, CO : Middle School or Under
|
0 Participants
|
0 Participants
|
27 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Baltimore : College Degree
|
0 Participants
|
0 Participants
|
4 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Baltimore : High School/Some College
|
0 Participants
|
25 Participants
|
75 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Baltimore : Middle School or Under
|
0 Participants
|
2 Participants
|
32 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Bronx : College Degree
|
0 Participants
|
1 Participants
|
53 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Bronx : High School/Some College
|
0 Participants
|
1 Participants
|
190 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Bronx : Middle School or Under
|
0 Participants
|
1 Participants
|
201 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Chicago : College Degree
|
2 Participants
|
10 Participants
|
23 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Chicago : High School/Some College
|
16 Participants
|
38 Participants
|
82 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Chicago : Middle School or Under
|
2 Participants
|
4 Participants
|
33 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Cincinnati : College Degree
|
0 Participants
|
0 Participants
|
41 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Cincinnati : High School/Some College
|
4 Participants
|
5 Participants
|
58 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Cincinnati : Middle School or Under
|
0 Participants
|
0 Participants
|
5 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Harlem : College Degree
|
0 Participants
|
20 Participants
|
72 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Harlem : High School/Some College
|
0 Participants
|
38 Participants
|
192 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Harlem : Middle School or Under
|
0 Participants
|
13 Participants
|
85 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Houston : College Degree
|
1 Participants
|
2 Participants
|
33 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Houston : High School/Some College
|
0 Participants
|
8 Participants
|
67 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Houston : Middle School or Under
|
0 Participants
|
1 Participants
|
46 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Miami : College Degree
|
0 Participants
|
0 Participants
|
36 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Miami : High School/Some College
|
0 Participants
|
0 Participants
|
130 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Miami : Middle School or Under
|
0 Participants
|
0 Participants
|
47 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
New Orleans : College Degree
|
1 Participants
|
0 Participants
|
30 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
New Orleans : High School/Some College
|
10 Participants
|
6 Participants
|
93 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
New Orleans : Middle School or Under
|
4 Participants
|
2 Participants
|
31 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
New York - Columbia : College Degree
|
0 Participants
|
11 Participants
|
28 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
New York - Columbia : High School/Some College
|
0 Participants
|
22 Participants
|
39 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
New York - Columbia : Middle School or Under
|
0 Participants
|
8 Participants
|
13 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Newark : College Degree
|
0 Participants
|
20 Participants
|
22 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Newark : High School/Some College
|
0 Participants
|
26 Participants
|
90 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Newark : Middle School or Under
|
0 Participants
|
1 Participants
|
17 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Philadelphia : College Degree
|
0 Participants
|
11 Participants
|
24 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Philadelphia : High School/Some College
|
0 Participants
|
37 Participants
|
149 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Philadelphia : Middle School or Under
|
0 Participants
|
9 Participants
|
32 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Pittsburgh : College Degree
|
1 Participants
|
9 Participants
|
36 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Pittsburgh : High School/Some College
|
0 Participants
|
10 Participants
|
48 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Pittsburgh : Middle School or Under
|
0 Participants
|
0 Participants
|
2 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Ponce, Puerto Rico : College Degree
|
0 Participants
|
6 Participants
|
34 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Ponce, Puerto Rico : High School/Some College
|
6 Participants
|
13 Participants
|
58 Participants
|
|
To Assess Association Between Education and SARS-CoV-2 Infection and/or Seroprevalence
Ponce, Puerto Rico : Middle School or Under
|
0 Participants
|
1 Participants
|
36 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: These estimated numbers of people in the given cities with active COVID-19 were only calculated for the general population recruited from community venues, since we used US Census Data to statistically weight participants in the sample. We did not have any census data to estimate these populations for Senior Living Facilities or Outpatient Healthcare Facilities.
The purpose of this outcome is to estimate the total number of people in each city's catchment area that had active COVID-19, using data collected January-July 2021 from the CoVPN5002 study and using 2020 US Census Data given the zip codes from defined recruitment catchment area at each city.
Outcome measures
| Measure |
Senior Living Facilities
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=20998 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those With Active COVID-19
Houston
|
—
|
—
|
96465 number of individuals in population
Interval 16.0 to 372143.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those With Active COVID-19
Atlanta
|
—
|
—
|
2471 number of individuals in population
Interval 3.0 to 6303.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those With Active COVID-19
Aurora, CO
|
—
|
—
|
4709 number of individuals in population
Interval 3.0 to 11214.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those With Active COVID-19
Baltimore
|
—
|
—
|
29240 number of individuals in population
Interval 12.0 to 148690.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those With Active COVID-19
Bronx
|
—
|
—
|
23001 number of individuals in population
Interval 14233.0 to 31770.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those With Active COVID-19
Chicago
|
—
|
—
|
31815 number of individuals in population
Interval 286.0 to 63344.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those With Active COVID-19
Cincinnati
|
—
|
—
|
23793 number of individuals in population
Interval 7616.0 to 39970.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those With Active COVID-19
Harlem
|
—
|
—
|
13279 number of individuals in population
Interval 4651.0 to 21908.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those With Active COVID-19
Miami
|
—
|
—
|
15882 number of individuals in population
Interval 808.0 to 30956.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those With Active COVID-19
New Orleans
|
—
|
—
|
9240 number of individuals in population
Interval 2327.0 to 16153.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those With Active COVID-19
New York - Columbia
|
—
|
—
|
0 number of individuals in population
Interval 0.0 to 0.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those With Active COVID-19
Newark
|
—
|
—
|
469 number of individuals in population
Interval 1.0 to 2969.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those With Active COVID-19
Philadelphia
|
—
|
—
|
29060 number of individuals in population
Interval 8945.0 to 49175.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those With Active COVID-19
Pittsburgh
|
—
|
—
|
1983 number of individuals in population
Interval 4.0 to 13071.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those With Active COVID-19
Ponce, Puerto Rico
|
—
|
—
|
1482 number of individuals in population
Interval 867.0 to 2098.0
|
SECONDARY outcome
Timeframe: BaselinePopulation: These estimated numbers of people in the given cities who have serologic evidence of recent and/or past SARS-CoV-2 infection were only calculated for the general population recruited from community venues, since we used US Census Data to statistically weight participants in the sample. We did not have any census data to estimate these populations for Senior Living Facilities or Outpatient Healthcare Facilities.
The purpose of this outcome is to estimate the total number of people in each city's catchment area who have serologic evidence of recent and/or past SARS-CoV-2 infection, using data collected January-July 2021 from the CoVPN5002 study and using 2020 US Census Data given the zip codes from defined recruitment catchment area at each city.
Outcome measures
| Measure |
Senior Living Facilities
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=21189 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Serologic Evidence of Recent and/or Past SARS-CoV-2 Infection
Atlanta
|
—
|
—
|
173755 number of individuals in population
Interval 132599.0 to 214911.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Serologic Evidence of Recent and/or Past SARS-CoV-2 Infection
Aurora, CO
|
—
|
—
|
199461 number of individuals in population
Interval 135011.0 to 263910.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Serologic Evidence of Recent and/or Past SARS-CoV-2 Infection
Baltimore
|
—
|
—
|
268590 number of individuals in population
Interval 108.0 to 600514.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Serologic Evidence of Recent and/or Past SARS-CoV-2 Infection
Bronx
|
—
|
—
|
253250 number of individuals in population
Interval 226519.0 to 279981.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Serologic Evidence of Recent and/or Past SARS-CoV-2 Infection
Chicago
|
—
|
—
|
567397 number of individuals in population
Interval 376477.0 to 758317.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Serologic Evidence of Recent and/or Past SARS-CoV-2 Infection
Cincinnati
|
—
|
—
|
118851 number of individuals in population
Interval 80433.0 to 157268.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Serologic Evidence of Recent and/or Past SARS-CoV-2 Infection
Harlem
|
—
|
—
|
213362 number of individuals in population
Interval 183164.0 to 243560.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Serologic Evidence of Recent and/or Past SARS-CoV-2 Infection
Houston
|
—
|
—
|
693472 number of individuals in population
Interval 146.0 to 2611419.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Serologic Evidence of Recent and/or Past SARS-CoV-2 Infection
Miami
|
—
|
—
|
376509 number of individuals in population
Interval 313969.0 to 439049.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Serologic Evidence of Recent and/or Past SARS-CoV-2 Infection
New Orleans
|
—
|
—
|
71281 number of individuals in population
Interval 54217.0 to 88346.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Serologic Evidence of Recent and/or Past SARS-CoV-2 Infection
New York - Columbia
|
—
|
—
|
440887 number of individuals in population
Interval 331644.0 to 550131.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Serologic Evidence of Recent and/or Past SARS-CoV-2 Infection
Newark
|
—
|
—
|
126548 number of individuals in population
Interval 71527.0 to 181569.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Serologic Evidence of Recent and/or Past SARS-CoV-2 Infection
Philadelphia
|
—
|
—
|
203139 number of individuals in population
Interval 99665.0 to 306614.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Serologic Evidence of Recent and/or Past SARS-CoV-2 Infection
Pittsburgh
|
—
|
—
|
81970 number of individuals in population
Interval 47744.0 to 116196.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Serologic Evidence of Recent and/or Past SARS-CoV-2 Infection
Ponce, Puerto Rico
|
—
|
—
|
6796 number of individuals in population
Interval 5463.0 to 8130.0
|
SECONDARY outcome
Timeframe: BaselinePopulation: These estimated numbers of people in the given cities who have negative RNA and serologic SARS-CoV-2 tests were only calculated for the general population recruited from community venues, since we used US Census Data to statistically weight participants in the sample. We did not have any census data to estimate these populations for Senior Living Facilities or Outpatient Healthcare Facilities.
The purpose of this outcome is to estimate the total number of people in each city's catchment area that have negative RNA and serologic SARS-CoV-2 tests, using data collected January-July 2021 from the CoVPN5002 study and using 2020 US Census Data given the zip codes from defined recruitment catchment area at each city.
Outcome measures
| Measure |
Senior Living Facilities
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=21189 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Negative RNA and Serologic SARS-CoV-2 Tests
Atlanta
|
—
|
—
|
1489883 number of individuals in population
Interval 1362673.0 to 1617093.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Negative RNA and Serologic SARS-CoV-2 Tests
Aurora, CO
|
—
|
—
|
1592673 number of individuals in population
Interval 1356298.0 to 1829049.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Negative RNA and Serologic SARS-CoV-2 Tests
Baltimore
|
—
|
—
|
1572296 number of individuals in population
Interval 303835.0 to 2008325.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Negative RNA and Serologic SARS-CoV-2 Tests
Bronx
|
—
|
—
|
1140101 number of individuals in population
Interval 1107214.0 to 1172989.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Negative RNA and Serologic SARS-CoV-2 Tests
Chicago
|
—
|
—
|
4132284 number of individuals in population
Interval 2958803.0 to 5198275.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Negative RNA and Serologic SARS-CoV-2 Tests
Cincinnati
|
—
|
—
|
1089114 number of individuals in population
Interval 942592.0 to 1235636.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Negative RNA and Serologic SARS-CoV-2 Tests
Harlem
|
—
|
—
|
1237756 number of individuals in population
Interval 1079223.0 to 1396289.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Negative RNA and Serologic SARS-CoV-2 Tests
Houston
|
—
|
—
|
3896726 number of individuals in population
Interval 912.0 to 5007307.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Negative RNA and Serologic SARS-CoV-2 Tests
Miami
|
—
|
—
|
2190511 number of individuals in population
Interval 2109455.0 to 2271567.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Negative RNA and Serologic SARS-CoV-2 Tests
New Orleans
|
—
|
—
|
715864 number of individuals in population
Interval 647102.0 to 784626.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Negative RNA and Serologic SARS-CoV-2 Tests
New York - Columbia
|
—
|
—
|
2570396 number of individuals in population
Interval 2438258.0 to 2702534.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Negative RNA and Serologic SARS-CoV-2 Tests
Newark
|
—
|
—
|
629330 number of individuals in population
Interval 334125.0 to 795404.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Negative RNA and Serologic SARS-CoV-2 Tests
Philadelphia
|
—
|
—
|
1277380 number of individuals in population
Interval 816088.0 to 11579075.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Negative RNA and Serologic SARS-CoV-2 Tests
Pittsburgh
|
—
|
—
|
1051355 number of individuals in population
Interval 922970.0 to 1179741.0
|
|
To Estimate Potential Size of Populations for Referral to COVID-19 Prevention and Treatment Studies for Those Who Have Negative RNA and Serologic SARS-CoV-2 Tests
Ponce, Puerto Rico
|
—
|
—
|
132289 number of individuals in population
Interval 130043.0 to 134535.0
|
SECONDARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who had a non-missing response to the question regarding wearing a mask in public spaces. Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older, however this question was not asked for children under 10 years old.
Proportions of participants who responded "All of the time" or Most of the time" on a 5-point Likert Scale for a question on whether they wore a face mask in public spaces.
Outcome measures
| Measure |
Senior Living Facilities
n=753 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=3012 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=20605 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Face-masking
Cincinnati
|
9 Participants
|
32 Participants
|
924 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Face-masking
Harlem
|
0 Participants
|
455 Participants
|
2192 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Face-masking
Houston
|
24 Participants
|
118 Participants
|
1005 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Face-masking
Miami
|
0 Participants
|
0 Participants
|
1276 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Face-masking
New Orleans
|
194 Participants
|
58 Participants
|
1493 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Face-masking
Chicago
|
88 Participants
|
325 Participants
|
1104 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Face-masking
Atlanta
|
0 Participants
|
64 Participants
|
733 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Face-masking
Aurora, CO
|
0 Participants
|
0 Participants
|
553 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Face-masking
Baltimore
|
0 Participants
|
135 Participants
|
749 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Face-masking
Bronx
|
0 Participants
|
13 Participants
|
2111 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Face-masking
New York - Columbia
|
0 Participants
|
247 Participants
|
440 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Face-masking
Newark
|
0 Participants
|
249 Participants
|
743 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Face-masking
Philadelphia
|
0 Participants
|
476 Participants
|
1332 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Face-masking
Pittsburgh
|
36 Participants
|
130 Participants
|
824 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Face-masking
Ponce, Puerto Rico
|
236 Participants
|
381 Participants
|
2480 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who had a non-missing response to the question regarding using six feet of distance from others in public spaces. Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older, however this question was not asked for children under 13 years old.
Proportions of participants who responded "All of the time" or Most of the time" on a 5-point Likert Scale for a question on whether they maintained six feet of distance from others in public spaces.
Outcome measures
| Measure |
Senior Living Facilities
n=755 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=3023 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=20158 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Six-feet Distancing
Atlanta
|
0 Participants
|
61 Participants
|
648 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Six-feet Distancing
Aurora, CO
|
0 Participants
|
0 Participants
|
549 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Six-feet Distancing
Baltimore
|
0 Participants
|
129 Participants
|
709 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Six-feet Distancing
Bronx
|
0 Participants
|
10 Participants
|
1724 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Six-feet Distancing
Chicago
|
78 Participants
|
298 Participants
|
972 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Six-feet Distancing
Cincinnati
|
8 Participants
|
33 Participants
|
827 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Six-feet Distancing
Harlem
|
0 Participants
|
418 Participants
|
1951 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Six-feet Distancing
Houston
|
19 Participants
|
99 Participants
|
841 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Six-feet Distancing
Miami
|
0 Participants
|
0 Participants
|
1177 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Six-feet Distancing
New Orleans
|
168 Participants
|
55 Participants
|
1274 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Six-feet Distancing
New York - Columbia
|
0 Participants
|
212 Participants
|
348 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Six-feet Distancing
Newark
|
0 Participants
|
230 Participants
|
684 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Six-feet Distancing
Philadelphia
|
0 Participants
|
401 Participants
|
1159 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Six-feet Distancing
Pittsburgh
|
33 Participants
|
107 Participants
|
748 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Six-feet Distancing
Ponce, Puerto Rico
|
238 Participants
|
341 Participants
|
2251 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who had a non-missing response to the question regarding time spent in public spaces. Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older, however this question was not asked for children under 10 years old.
Proportions of participants who responded "Never" or "Almost Never" on a 5-point Likert Scale for a question on whether they spend time in public spaces, gatherings, and crowds.
Outcome measures
| Measure |
Senior Living Facilities
n=753 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=3021 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=20503 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Avoiding Public Spaces
Atlanta
|
0 Participants
|
41 Participants
|
406 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Avoiding Public Spaces
Aurora, CO
|
0 Participants
|
0 Participants
|
334 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Avoiding Public Spaces
Baltimore
|
0 Participants
|
97 Participants
|
561 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Avoiding Public Spaces
Bronx
|
0 Participants
|
12 Participants
|
1375 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Avoiding Public Spaces
Chicago
|
76 Participants
|
244 Participants
|
742 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Avoiding Public Spaces
Cincinnati
|
9 Participants
|
20 Participants
|
558 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Avoiding Public Spaces
Harlem
|
0 Participants
|
335 Participants
|
1570 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Avoiding Public Spaces
Houston
|
24 Participants
|
69 Participants
|
524 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Avoiding Public Spaces
Miami
|
0 Participants
|
0 Participants
|
814 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Avoiding Public Spaces
New Orleans
|
162 Participants
|
49 Participants
|
1073 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Avoiding Public Spaces
New York - Columbia
|
0 Participants
|
163 Participants
|
256 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Avoiding Public Spaces
Newark
|
0 Participants
|
163 Participants
|
467 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Avoiding Public Spaces
Philadelphia
|
0 Participants
|
315 Participants
|
802 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Avoiding Public Spaces
Pittsburgh
|
28 Participants
|
71 Participants
|
474 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Avoiding Public Spaces
Ponce, Puerto Rico
|
260 Participants
|
221 Participants
|
1700 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: The number of people analyzed here is different than the total enrolled cohorts because we only include those participants who had a non-missing response to the question regarding the likelihood to receive an approved vaccine for COVID-19. Participants recruited from Senior Living Facilities and Outpatient Healthcare Facilities were aged 18 and older. Participants recruited from Community Venues were aged 2 months and older.
Proportions of participants who responded "Very likely", "Likely", or "Already Received" for a question on their likelihood to receive an approved vaccine for COVID-19.
Outcome measures
| Measure |
Senior Living Facilities
n=766 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=3026 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
n=21540 Participants
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Vaccine Willingness
Chicago
|
95 Participants
|
272 Participants
|
977 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Vaccine Willingness
Atlanta
|
0 Participants
|
74 Participants
|
756 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Vaccine Willingness
Aurora, CO
|
0 Participants
|
0 Participants
|
673 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Vaccine Willingness
Baltimore
|
0 Participants
|
89 Participants
|
611 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Vaccine Willingness
Bronx
|
0 Participants
|
14 Participants
|
1728 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Vaccine Willingness
Cincinnati
|
8 Participants
|
28 Participants
|
939 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Vaccine Willingness
Harlem
|
0 Participants
|
365 Participants
|
1719 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Vaccine Willingness
Houston
|
32 Participants
|
130 Participants
|
947 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Vaccine Willingness
Miami
|
0 Participants
|
0 Participants
|
1014 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Vaccine Willingness
New Orleans
|
184 Participants
|
57 Participants
|
1378 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Vaccine Willingness
New York - Columbia
|
0 Participants
|
227 Participants
|
461 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Vaccine Willingness
Newark
|
0 Participants
|
189 Participants
|
635 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Vaccine Willingness
Philadelphia
|
0 Participants
|
410 Participants
|
1197 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Vaccine Willingness
Pittsburgh
|
44 Participants
|
113 Participants
|
926 Participants
|
|
To Assess Knowledge, Attitudes, and Behavior About SARS-CoV-2 and COVID-19 Through a Study Questionnaire: Vaccine Willingness
Ponce, Puerto Rico
|
363 Participants
|
461 Participants
|
2208 Participants
|
SECONDARY outcome
Timeframe: BaselinePopulation: Sub-sample of participants enrolled from Philadelphia and Cincinnati sites who provided both a nasal swab and saliva sample. This is a sub-study from these two sites only. We present a confusion matrix comparing lab results of Nasal Swabs to Saliva Samples. The columns presented are the Nasal Swab results, and the rows are the Saliva Sample results from this testing.
Concordance between saliva and nasal SARS-CoV-2 PCR results among a sub-sample of participants.
Outcome measures
| Measure |
Senior Living Facilities
n=647 Participants
Adults residing in senior living facilities (nursing homes, assisted or independent living facilities)
|
Outpatient Healthcare Facilities
n=10 Participants
Adults attending outpatient healthcare in neighborhoods of selected research sites
|
Community Venues
Adults and children (\>2 months) in neighborhoods of selected research sites
|
|---|---|---|---|
|
To Assess Performance Characteristics of PCR-based and Serologic SARS-CoV-2 Tests Using Saliva Samples
Saliva PCR: Negative
|
646 Participants
|
3 Participants
|
—
|
|
To Assess Performance Characteristics of PCR-based and Serologic SARS-CoV-2 Tests Using Saliva Samples
Saliva PCR: Positive
|
1 Participants
|
7 Participants
|
—
|
Adverse Events
Senior Living Facilities
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Outpatient Healthcare Facilities
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
General Communities
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place